Your health is our priority, and we are committed to providing personalized care based on the latest medical guidelines
declares having received consulting honoraria from ANI Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Oramed, and stock options from AltPep
Drugs for weight loss may increase the risk of kidney problems, including acute kidney injury, diabetic kidney disease, chronic kidney disease, and kidney failure
This dual-hormone approach is a major step forward in metabolic medicine
No, GLP-1s are considered adjunctsthey do not replace disease-modifying drugs but can be a helpful addition in select patients to improve metabolic and inflammatory status.
Fast shipping and very responsive in emails